JP2022552286A5 - - Google Patents

Info

Publication number
JP2022552286A5
JP2022552286A5 JP2022521307A JP2022521307A JP2022552286A5 JP 2022552286 A5 JP2022552286 A5 JP 2022552286A5 JP 2022521307 A JP2022521307 A JP 2022521307A JP 2022521307 A JP2022521307 A JP 2022521307A JP 2022552286 A5 JP2022552286 A5 JP 2022552286A5
Authority
JP
Japan
Prior art keywords
composition according
mrnas
sting
administration
encoding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022521307A
Other languages
English (en)
Japanese (ja)
Other versions
JP7650873B2 (ja
JP2022552286A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/054952 external-priority patent/WO2021072172A1/en
Publication of JP2022552286A publication Critical patent/JP2022552286A/ja
Publication of JP2022552286A5 publication Critical patent/JP2022552286A5/ja
Priority to JP2025038216A priority Critical patent/JP2025090723A/ja
Application granted granted Critical
Publication of JP7650873B2 publication Critical patent/JP7650873B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022521307A 2019-10-09 2020-10-09 メッセンジャーrnaの組成物、方法および使用 Active JP7650873B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025038216A JP2025090723A (ja) 2019-10-09 2025-03-11 メッセンジャーrnaの組成物、方法および使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962913035P 2019-10-09 2019-10-09
US62/913,035 2019-10-09
PCT/US2020/054952 WO2021072172A1 (en) 2019-10-09 2020-10-09 Compositions, methods and uses of messenger rna

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025038216A Division JP2025090723A (ja) 2019-10-09 2025-03-11 メッセンジャーrnaの組成物、方法および使用

Publications (3)

Publication Number Publication Date
JP2022552286A JP2022552286A (ja) 2022-12-15
JP2022552286A5 true JP2022552286A5 (cg-RX-API-DMAC7.html) 2023-10-17
JP7650873B2 JP7650873B2 (ja) 2025-03-25

Family

ID=73040270

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022521307A Active JP7650873B2 (ja) 2019-10-09 2020-10-09 メッセンジャーrnaの組成物、方法および使用
JP2025038216A Pending JP2025090723A (ja) 2019-10-09 2025-03-11 メッセンジャーrnaの組成物、方法および使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025038216A Pending JP2025090723A (ja) 2019-10-09 2025-03-11 メッセンジャーrnaの組成物、方法および使用

Country Status (6)

Country Link
US (2) US12076438B2 (cg-RX-API-DMAC7.html)
EP (2) EP4529928A3 (cg-RX-API-DMAC7.html)
JP (2) JP7650873B2 (cg-RX-API-DMAC7.html)
CN (1) CN114728176B (cg-RX-API-DMAC7.html)
ES (1) ES3028783T3 (cg-RX-API-DMAC7.html)
WO (1) WO2021072172A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023004299A (es) * 2020-10-13 2023-07-07 Univ Pennsylvania Direccionamiento de células t cd4+ in vivo para terapeuticos de arnm.
CN115960906A (zh) * 2022-05-07 2023-04-14 苏州科锐迈德生物医药科技有限公司 用于抗肿瘤免疫治疗的rna组合物、rna制剂及用途
WO2024164006A2 (en) * 2023-02-03 2024-08-08 The Regents Of The University Of California Self-amplifying rna form of a constitutively-active sting protein for enhancing t-cell response to antigenpresenting cells
WO2024240962A1 (en) * 2023-05-25 2024-11-28 Ethris Gmbh Gm-csf-encoding nucleic acids, pharmaceutical compositions, methods and uses thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
FR2645866B1 (fr) 1989-04-17 1991-07-05 Centre Nat Rech Scient Nouvelles lipopolyamines, leur preparation et leur emploi
US5334761A (en) 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5744335A (en) 1995-09-19 1998-04-28 Mirus Corporation Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein
CA2569664C (en) 2004-06-07 2013-07-16 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering rna
PL2578685T3 (pl) 2005-08-23 2020-01-31 The Trustees Of The University Of Pennsylvania Rna zawierający zmodyfikowane nukleozydy i sposoby jego zastosowania
AU2009303345B2 (en) 2008-10-09 2015-08-20 Arbutus Biopharma Corporation Improved amino lipids and methods for the delivery of nucleic acids
WO2010053572A2 (en) 2008-11-07 2010-05-14 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
EA022786B1 (ru) 2009-07-31 2016-03-31 Этрис Гмбх Рнк с комбинацией из немодифицированных и модифицированных нуклеотидов для экспрессии белков
US8326547B2 (en) 2009-10-07 2012-12-04 Nanjingjinsirui Science & Technology Biology Corp. Method of sequence optimization for improved recombinant protein expression using a particle swarm optimization algorithm
SI2506857T1 (en) 2009-12-01 2018-08-31 Translate Bio, Inc. Delivery of mRNA for the enrichment of proteins and enzymes in human genetic diseases
EP4074693A1 (en) 2011-06-08 2022-10-19 Translate Bio, Inc. Cleavable lipids
KR20220025112A (ko) 2011-06-08 2022-03-03 샤이어 휴먼 지네틱 테라피즈 인크. Mrna 전달을 위한 지질 나노입자 조성물 및 방법
US9512073B2 (en) 2011-10-27 2016-12-06 Massachusetts Institute Of Technology Amino acid-, peptide-and polypeptide-lipids, isomers, compositions, and uses thereof
EA201492055A1 (ru) * 2012-06-08 2015-11-30 Шир Хьюман Дженетик Терапис, Инк. ИНГАЛЯЦИОННАЯ ДОСТАВКА мРНК В НЕЛЕГОЧНЫЕ КЛЕТКИ-МИШЕНИ
EA201591229A1 (ru) 2013-03-14 2016-01-29 Шир Хьюман Дженетик Терапис, Инк. Способы очистки матричной рнк
EA201591283A1 (ru) 2013-03-14 2016-02-29 Шир Хьюман Дженетик Терапис, Инк. Количественная оценка эффективности кэп матричной рнк
ES3032935T3 (en) * 2013-10-22 2025-07-29 Translate Bio Inc Lipid formulations for delivery of messenger rna
EP4729528A3 (en) 2014-04-25 2026-06-24 Translate Bio, Inc. Methods for purification of messenger rna
AU2016251687C1 (en) * 2015-04-22 2023-07-27 CureVac SE RNA containing composition for treatment of tumor diseases
RS63625B1 (sr) * 2016-05-18 2022-10-31 Modernatx Inc Kombinacije irnk koje kodiraju imunomodulirajuće polipeptide i njihova upotreba
CA3042015A1 (en) * 2016-10-26 2018-05-03 Modernatx, Inc. Messenger ribonucleic acids for enhancing immune responses and methods of use thereof
MX2019009070A (es) * 2017-02-01 2019-10-30 Modernatx Inc Composiciones de arnm terapeuticas inmunomoduladoras que codifican peptidos de mutacion de oncogenes de activacion.
KR20240144261A (ko) 2017-02-28 2024-10-02 사노피 치료적 rna
AU2018270111B2 (en) 2017-05-18 2022-07-14 Modernatx, Inc. Polynucleotides encoding tethered interleukin-12 (IL12) polypeptides and uses thereof
TW202003032A (zh) 2018-03-23 2020-01-16 美商科迪亞克生物科學公司 包含s t i n g 促效劑之胞外囊泡
JP7256824B2 (ja) 2018-04-25 2023-04-12 エスリス ゲーエムベーハー 粒子状製剤用の凍結保護剤
EP3880174A2 (en) 2018-11-12 2021-09-22 Translate Bio, Inc. Methods for inducing immune tolerance

Similar Documents

Publication Publication Date Title
EP3247328B1 (en) Methods, compositions, and systems for delivering therapeutic and diagnostic agents into cells
JP5911471B2 (ja) ポリグルタミン酸ナノ粒子およびcd40アゴニストなどのポリペプチドを含む組成物
US20210369862A1 (en) Therapeutic nanoparticles and methods of use thereof
JP2021525725A5 (cg-RX-API-DMAC7.html)
Liao et al. Acteoside alleviates blood–brain barrier damage induced by ischemic stroke through inhibiting microglia HMGB1/TLR4/NLRP3 signaling
KR20170101913A (ko) 암 면역치료의 보조제로서의 브로모도메인 억제제
Andreakos et al. Amphoteric liposomes enable systemic antigen‐presenting cell–directed delivery of CD40 antisense and are therapeutically effective in experimental arthritis
JP2002529421A (ja) 血管過浸透性の阻害方法
EP3494994A1 (en) Combinations of ripk1- and ikk-inhibitors for the prevention or treatment of immune diseases
Amm et al. Combined modality therapy with TRAIL or agonistic death receptor antibodies
CA2376894C (en) Pharmaceutical composition comprising a protein and an ectoine
JP2026021440A (ja) がん治療のための治療用ペプチドに関する方法および組成物
US20090162426A1 (en) Use of a Compound with RANKL Activity
US7666989B2 (en) Recombinant protein having an anti-cancer effect, its encoding gene and uses thereof
EP1481007B1 (en) Spheron components useful in determining compounds capable of treating symptoms of alzheimer's disease, treatments and animal models produced therefrom
EP2992879B1 (en) Pharmaceutical composition for inhibiting autophagy of motor neurons and use thereof
IL277602B1 (en) P2rx7 modulators in therapy
JP2009520774A (ja) コンブレタスタチンおよび抗癌剤を含む組合せ
Tashiro et al. Early Effects of β, β′‐Iminodipropionitrile on Tubulin Solubility and Neurofilament Phosphorylation in the Axon
JP6987271B2 (ja) 新規キノカルコン化合物、及びがん又は炎症を治療するためのその用途
EP4039276A1 (en) Inhibitor against expression of immune checkpoint molecule
CN104815322A (zh) 用于头颈部肿瘤联合治疗的制剂及其用途
Hirsh-Raccah Treatment of cardiac Amyloidosis—Disease modifying therapies in ATTR: Pharmacological point of view
US8268888B2 (en) Therapy of malignant neoplasias
EP2110384B1 (en) Hepatopoietin and use thereof